Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Common Equity (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Common Equity for 15 consecutive years, with $1.1 billion as the latest value for Q1 2026.

  • For Q1 2026, Common Equity fell 24.37% year-over-year to $1.1 billion; the TTM value through Mar 2026 reached $1.1 billion, down 24.37%, while the annual FY2025 figure was $1.2 billion, 22.57% down from the prior year.
  • Common Equity hit $1.1 billion in Q1 2026 for Agios Pharmaceuticals, down from $1.2 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.6 billion in Q3 2024 and bottomed at $660.5 million in Q2 2024.
  • Average Common Equity over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2026.
  • Year-over-year, Common Equity tumbled 47.43% in 2022 and then surged 107.35% in 2025.
  • Agios Pharmaceuticals' Common Equity stood at $1.1 billion in 2022, then dropped by 26.33% to $811.0 million in 2023, then soared by 90.0% to $1.5 billion in 2024, then dropped by 22.57% to $1.2 billion in 2025, then fell by 7.04% to $1.1 billion in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $1.1 billion, $1.2 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.